Quest Diagnostics Incorporated (DGX): Price and Financial Metrics
Quest Diagnostics Incorporated (DGX)
Today's Latest Price: $76.72 USD
Updated Apr 1 1:50pm
Add DGX to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 58 in Medical - Diagnostics/Research
See all "A" rated Strong Buy stocks
DGX Stock Summary
- Quest Diagnostics Inc's market capitalization of $10,580,317,791 is ahead of 88.7% of US-listed equities.
- Of note is the ratio of Quest Diagnostics Inc's sales and general administrative expense to its total operating expenses; 86.27% of US stocks have a lower such ratio.
- The volatility of Quest Diagnostics Inc's share price is greater than that of just 5.47% US stocks with at least 200 days of trading history.
- Stocks that are quantitatively similar to DGX, based on their financial statements, market capitalization, and price volatility, are SWK, BRO, WRK, HII, and MKC.
- Visit DGX's SEC page to see the company's official filings. To visit the company's web site, go to www.questdiagnostics.com.
DGX Stock Price Chart More Charts
DGX Price/Volume Stats
| Current price | $76.72 | 52-week high | $118.58 |
| Prev. close | $80.30 | 52-week low | $73.21 |
| Day low | $74.11 | Volume | 1,523,826 |
| Day high | $77.92 | Avg. volume | 1,573,976 |
| 50-day MA | $102.31 | Dividend yield | 2.64% |
| 200-day MA | $103.24 | Market Cap | 10.24B |
Quest Diagnostics Incorporated (DGX) Company Bio
Quest Diagnostics provides diagnostic testing information services in the United States and internationally. The company offers clinical testing services, such as routine testing, gene-based and esoteric testing, anatomic pathology services, and drugs-of-abuse testing, as well as related services and insights; laboratory testing services for new drugs, vaccines, and medical devices, analytic, on-site prevention, and wellness services, and risk assessment services for the life insurance industry. The company was founded in 1967 and is founded in Madison, New Jersey.
DGX Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $76.72 | $138.37 | 72% |
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Quest Diagnostics Inc. To summarize, we found that Quest Diagnostics Inc ranked in the 54th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 73.17% on a DCF basis. In terms of the factors that were most noteworthy in this DCF analysis for DGX, they are:
- Quest Diagnostics Inc's weighted average cost of capital (WACC) is 6%; for context, that number is higher than only 15.67% of tickers in our DCF set.
- Relative to other stocks in its sector (Healthcare), Quest Diagnostics Inc has a reliance on debt greater than 71.34% of them.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | 69% |
| 1% | 71% |
| 2% | 72% |
| 3% | 74% |
| 4% | 76% |
| 5% | 77% |
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as DGX, try SNY, FONR, NVST, DVA, and IONS.
Top Stories View All
5 Fitness Stocks for the “Modern World”
How Should Cannabis Investors Interpret Cronos Group's Earnings Report?
3 Reasons for Economic Hope in a Sea of Darkness
NYSE Suspends Trading for CannTrust (CTST) and Commences Delisting Process
Best & Worst Performing Stock Industries for March 31, 2020
View All Top Stories
Loading social stream, please wait...